BPMC Key Statistics, Chart & Performance
The current stock price of BPMC is 129.46 USD. In the past month the price increased by 0.96%. In the past year, price increased by 12.6%.
BPMC Latest News, Press Relases and Analysis
BPMC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About BPMC
Company Profile
Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 649 full-time employees. The company went IPO on 2015-04-30. The firm invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. The company has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. The company is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. The company is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Company Info
BLUEPRINT MEDICINES CORP
45 Sidney Street
Cambridge MASSACHUSETTS 02139 US
CEO: Jeffrey W. Albers
Employees: 649
Phone: 16173747580
BLUEPRINT MEDICINES CORP / BPMC FAQ
Can you describe the business of BLUEPRINT MEDICINES CORP?
Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 649 full-time employees. The company went IPO on 2015-04-30. The firm invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. The company has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. The company is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. The company is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
What is the stock price of BLUEPRINT MEDICINES CORP today?
The current stock price of BPMC is 129.46 USD. The price increased by 0.14% in the last trading session.
What is the dividend status of BLUEPRINT MEDICINES CORP?
BPMC does not pay a dividend.
What is the ChartMill technical and fundamental rating of BPMC stock?
BPMC has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of BLUEPRINT MEDICINES CORP (BPMC) based on its PE ratio?
BLUEPRINT MEDICINES CORP (BPMC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.22).
How many employees does BLUEPRINT MEDICINES CORP have?
BLUEPRINT MEDICINES CORP (BPMC) currently has 649 employees.
BPMC Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to BPMC. When comparing the yearly performance of all stocks, BPMC is one of the better performing stocks in the market, outperforming 87.01% of all stocks.
BPMC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BPMC. Both the profitability and financial health of BPMC have multiple concerns.
BPMC Financial Highlights
Over the last trailing twelve months BPMC reported a non-GAAP Earnings per Share(EPS) of -3.22. The EPS increased by 57.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.03% | ||
| ROE | -45.52% | ||
| Debt/Equity | 1.01 |
BPMC Forecast & Estimates
25 analysts have analysed BPMC and the average price target is 132.96 USD. This implies a price increase of 2.71% is expected in the next year compared to the current price of 129.46.
For the next year, analysts expect an EPS growth of 76.13% and a revenue growth 41.72% for BPMC